This is a first-in-human, 3-part study to investigate the safety, tolerability, and
effectiveness of ZW25 by itself and combined with selected chemotherapy agents in patients
with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor
2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs,
distributes, and eliminates ZW25 (pharmacokinetics or PK).